吉西他滨联合卡培他滨治疗转移性三阴乳腺癌32例临床观察

Clinical Observation of Gemcitabine Combined with Capecitabine in the Treatment of 32 Patients with Metastatic Triple-Negative Breast Cancer

目的探讨吉西他滨联合卡培他滨治疗转移性三阴乳腺癌的效果。方法对32例转移性三阴乳腺癌予吉西他滨联合卡培他滨方案化疗:吉西他滨1 g/m2静脉滴注,d 1、8;卡培他滨1250 mg/m2口服、2/d,d 1～14,3周为1个周期。2个周期后初步评价疗效,如肿瘤进展更换方案,有效者继续应用至少2个周期,共用4个周期后评价疗效及毒性反应。结果本组完全缓解(CR)1例,部分缓解(PR)13例,稳定(SD)12例,进展(PD)6例,总有效(CR+PR)率43.8%,临床获益(CBR)率为62.5%(20/32),主要毒性反应为骨髓抑制及手足综合征。结论吉西他滨联合卡培他滨治疗转移性三阴乳腺癌近期效果满意,毒性反应低,可作为二线化疗方案。

Objective To explore the effect of Gemcitabine combined with Capeeitabine in treatment of metastat- ic triple-negative breast cancer. Methods The 32 patients with metastatic triple-negative breast cancer were treated with Gemeitabine iv gtt 1g/m2 , d 1,8, and Capeeitabine po 1250 mg/m2 , 2/d , d 1-14. Three weeks was one cycle. Preliminary assessment of efficacy were preformed at two cycles after chemotherapy, program was changed if there was tumor progression, while effective patients were continued at least another two cycles. The efficacy and toxicity were evaluated at 4 cycles after treatment. Results There were 1 patient with complete response, 13 patients with partial re- sponse, 12 patients with stable disease and 6 patients with progression disease. The total effective rate was 43.8% （ 14/ 32）. Clinical benefit rate （CBR） was 62.5% （20/32）. The main toxic reactions were myelosuppression and hand-foot syndrome. Conclusion The method of Gemeitabine combined with Capeeitabine may be used as second-line therapy program in treatment of metastatic triple-negative breast cancer.